SBFMW · Sunshine Biopharma, Inc.

Sunshine Biopharma operates in pharmaceuticals through subsidiaries Nora Pharma, marketing 60 generic drugs in Canada, and Sunshine Canada selling OTC supplements, while advancing proprietary assets K1.1 mRNA lipid nanoparticle for liver cancer and SBFM-PL4 protease inhibitor against SARS coronaviruses. This positions the company across established generics revenue and high-risk development-stage innovation, though no specific revenue figures or market sizes are disclosed beyond Canadian generics focus. The $6 million best-efforts offering of 5.8 million Common Units at $1.03—each bundling one common share and two five-year Series C Warrants (initially exercisable at $1.03, with potential Share Combination Event reset to $0.535 floor post-stockholder approval)—targets working capital amid $9.1 million cash as of December 2025. Post-offering shares double to 10.8 million from 5 million, implying significant dilution, with net proceeds of $5 million available immediately due to no escrow minimum, though best-efforts nature risks shortfall. CEO Dr. Steve Slilaty dominates governance via 130,000 Series B Preferred shares (1,000 votes each, 100% of class), enabling prompt stockholder approval for warrant adjustments, while Intracoastal Capital holds 9.99% beneficially via warrants. Nasdaq listing persists under SBFM but with recent bid price violations below $1.00, prompting potential reverse split. Placement agent Aegis earns 7% commission plus 2% expenses, with 90-day lock-ups on insiders (10%+ holders) and company standstill barring new issuances. Key risks center on Nasdaq delisting threat reducing liquidity and fundraising, warrant toxicity enabling aggressive dilution on price drops, execution risks in clinical development without disclosed milestones, and CEO voting control limiting minority protections. Financials show $7 million liabilities against $23 million equity, with $75 million accumulated deficit signaling ongoing losses, though recent $9 million cash provides runway. Investors face high dilution potential from 15 million outstanding Series B Warrants ($2.07 exercise, adjustable) and this offering's warrants, alongside biotech development uncertainties, making this a speculative working capital lifeline rather than growth catalyst.